Results 71 to 80 of about 25,691 (210)

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks [PDF]

, 1995
Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ringopened hydroxy acid, is essential ...
Beijnen, J.H. (Jos), Boer-Dennert, M. (Maureen) de, Davies, B.E. (Brian), Maes, R. (Rudolf), Rosing, H. (Hilde), Schellens, J.H.M. (Jan), Verweij, J. (Jaap), Warmerdam, L.J. (Laurence) van   +7 more
core   +1 more source

Light‐Triggered Antibody‐Photosensitizer Conjugates Disrupt P‐Glycoprotein Function to Reverse Multidrug Resistance

Advanced Therapeutics, Volume 9, Issue 4, April 2026.
Advanced ovarian cancer has a poor prognosis largely due to chemoresistance driven by ATP‐binding cassette (ABC) drug efflux transporters, especially P‐glycoprotein (P‐gp, or ABCB1). While photodynamic therapy (PDT) with FDA‐approved benzoporphyrin derivative (BPD) can inhibit ABC transporters, BPD alone lacks cancer selectivity.
Kathryn L. McNaughton, Tanvi Kotta, Carla Arnau Del Valle, Kaitlyn A. Moore, Idrisa Rahman, Dana M. Roque, Huang‐Chiao Huang   +6 more
wiley   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U., Heinemann, Volker, Schalhorn, A., Stemmler, J., Weise, A.   +4 more
core   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

Case Reports in Oncology, 2014
Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease.
Donato Callegaro-Filho, John J. Kavanagh, Alpa M. Nick, Pedro T. Ramirez, Kathleen M. Schmeler   +4 more
doaj   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective

Autophagy Reports, 2023
Topoisomerase I inhibitors represent a widely used class of antineoplastic agents that promote both single-stranded and double-stranded breaks in the DNA of tumor cells, leading to tumor cell death.
Ahmed M. Elshazly, Polina A. Wright, Jingwen Xu, David A. Gewirtz   +3 more
doaj   +1 more source

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity [PDF]

, 2014
Photodynamic therapy is a minimally invasive and clinically approved procedure for eliminating selected malignant cells with specific light activation of a photosensitizer agent.
Lamberti, María Julia, Rivarola, Viviana, Rumie Vittar, Natalia Belen   +2 more
core   +1 more source

Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Shepeng Wei, Xuxu Xu, Jing Bao, Zhenjiang Pan   +3 more
wiley   +1 more source

Cancer Neuroscience: Innovative Conception and Emerging Strategy of Therapy

MedComm, Volume 7, Issue 4, April 2026.
In this review, we summarize nerve–cancer interactions and conclude two additional interactions, “perineural invasion” and “neuro‐microbic‐oncology.” Emphasizing the important role of nerves in tumor progression. The nervous system also contributes to the development of cancer comorbidities such as cancer depression and cognitive dysfunction.
Ting Wang, Zikai Dong, Yongfei Wang, Ziyi An, Siyuan Wang, Wei‐Lin Jin   +5 more
wiley   +1 more source